Article
Wnt/β-catenin pathway is a key signaling pathway to trastuzumab resistance in gastric cancer cells
2023-05-26
Abstract excerpt
Backgroud: Trastuzumab is the only approved target agent for the first-line treatment of human epidermal growth factor receptor-2 (HER-2) positive gastric cancer; however, trastuzumab resistance is a major problem in clinical practice. To comprehend the mechanism of trastuzumab resistance, we focused on the Wnt/β-catenin signaling pathway and its influence on the phenotypes and behavior of trastuzumab-resistant g...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 22991c59-ad5f-5d71-a5bd-77a4472125c1
- DOI
- 10.21203/rs.3.rs-2946372/v1
